[Domperidone as an anti-emetic in antineoplastic chemotherapy].
The antiemetic effects of domperidone in patients undergoing post-surgical cytostatic treatment for stomach and colorectal carcinoma have been evaluated. The study has been performed on 3 groups of patients treated with domperidone, metoclopramide and placebo respectively. The antiemetic activity of domperidone proved to be better than that of metoclopramide. No side effects were observed in patients treated with domperidone.
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001562:Benzimidazoles / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004294:Domperidone; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000601:surgery; D006801:Humans; D008297:Male; D008787:Metoclopramide / Q000627:therapeutic use*; D008875:Middle Aged; D009325:Nausea / Q000517:prevention & control; D010880:Piperidines / Q000627:therapeutic use*; D011182:Postoperative Care; D014839:Vomiting / Q000517:prevention & control
D000970:Antineoplastic Agents; D001562:Benzimidazoles; D010880:Piperidines; D004294:Domperidone; D008787:Metoclopramide
Il domperidone come antiemetico in corso di chemioterapie antiblastica.